| Literature DB >> 35782947 |
Nan Yao1, Yixue Yang1, Xiaotong Li1, Yuxiang Wang1, Ruirui Guo1, Xuhan Wang1, Jing Li1, Zechun Xie1, Bo Li1, Weiwei Cui2.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has recently become the most common liver disease with a global prevalence of over 25% and is expected to increase. Recently, experts have reached a consensus that "fatty liver disease associated with metabolic dysfunction or MAFLD" may be a more appropriate and inclusive definition than NAFLD. Like the former name NAFLD, MAFLD, as a manifestation of multiple system metabolic disorders involving the liver, has certain heterogeneity in its pathogenesis, clinical manifestations, pathological changes and natural outcomes. We found that there is a delicate dynamic balance among intestinal microflora, metabolites and host immune system to maintain a healthy intestinal environment and host health. On the contrary, this imbalance is related to diseases such as MAFLD. However, there are no clear studies on how dietary nutrients affect the intestinal environment and participate in the pathogenesis of MAFLD. This review summarizes the interactions among dietary nutrients, intestinal microbiota and MAFLD in an attempt to provide evidence for the use of dietary supplements to regulate liver function in patients with MAFLD. These dietary nutrients influence the development and progression of MAFLD mainly through the hepatic-intestinal axis by altering dietary energy absorption, regulating bile acid metabolism, changing intestinal permeability and producing ethanol. Meanwhile, the nutrients have the ability to combat MAFLD in terms of enriching abundance of intestinal microbiota, reducing Firmicutes/Bacteroidetes ratio and promoting abundance of beneficial gut microbes. Therefore, family therapy with MAFLD using a reasonable diet could be considered.Entities:
Keywords: MAFLD; NAFLD; dietary nutrients; fatty liver disease associated with metabolic dysfunction; intestinal-hepatic axis; non-alcoholic fatty liver disease
Year: 2022 PMID: 35782947 PMCID: PMC9247350 DOI: 10.3389/fnut.2022.906511
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Microorganisms used as probiotics.
|
|
|
|---|---|
|
|
|
| L.acidophilus | |
| L.bulgaricus | |
| L.casei | |
| L.crispatus | |
| L.fermentum | |
| L.gasseri | |
| L.johnsonii | |
| L.lactis | |
| L.plantarum | |
| L.reuteri | |
| L.rhamnosus GG | |
|
| |
| B.adolescentis | |
| B.animalis | |
| B.bifidum | |
| B.breve | |
| B.infantis | |
| B.lactis | |
| B.longum | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
Figure 1Digestion and absorption of nutrients.
Figure 2How nutrients affect MAFLD through intestinal microenvironment and microbiota. (A) Intestinal microbial-intestinal-liver axis; (B) Macro level evidence on the effect of nutrients on MAFLD; (C) The mechanisms by which nutrients affect MAFLD through the intestinal microenvironment and microflora. FFA, free fatty acids; Fiaf, fasting-induced adipocyte factor; LPL, lipoprotein lipase; MAFLD, fatty liver disease associated with metabolic dysfunction; SCFA, short-chain fatty acid; FXR, farnesol X receptor; TGR5, Takeda G protein-coupled receptor 5; BAs, bile acids; FGF 19, fibroblast growth factor 19.
Figure 3Interactions between nutrients, intestinal microbiota and MAFLD. (A) A low intestinal microbiota abundance in MAFLD patients; (B) Dietary interventions enrich the intestinal microbiota abundance of MAFLD patients; (C) An increased Firmicutes/Bacteroidetes(F/B) ratio in MAFLD patients; (D) Dietary interventions reduce F/B ratio of patients with MAFLD; (E) A reduced abundance of beneficial bacteria in MAFLD patients; (F) Dietary interventions promote abundance of beneficial gut microbes to reestablish the balance of gut microbes; (G) How nutrients affect MAFLD through intestinal microenvironment and microbiota.